Literature DB >> 27995086

Hepatocellular Carcinoma: The Role of Interventional Oncology.

Matteo Donadon1, Luigi Solbiati2, Laura Dawson3, Aisling Barry3, Gonzalo Sapisochin4, Paul D Greig4, Shuichiro Shiina5, Andrea Fontana1, Guido Torzilli1.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) remains a major health issue because of its increasing incidence and because of the complexity of its management. In addition to the traditional potentially curative treatments, i.e., liver transplantation and surgical resection, other new and emerging local therapies have been applied with promising results.
SUMMARY: Radiotherapy (RT) and interstitial treatments, such as radiofrequency ablation (RFA), microwave ablation (MWA), and irreversible electroporation (IRE), have recently opened new and interesting treatment scenarios for HCC and are associated with promising results in selected patients. Herein, we describe the emerging role of interventional oncology for the treatment of HCC and focus on the different Western and Eastern approaches. KEY MESSAGES: Modern RT and modern interstitial therapies, such as RFA, MWA, and IRE, should be considered for inclusion in HCC therapy guidelines.

Entities:  

Keywords:  IRE for HCC; MWA for HCC; RFA for HCC; Radiotherapy for HCC

Year:  2016        PMID: 27995086      PMCID: PMC5159721          DOI: 10.1159/000449346

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   11.740


  40 in total

1.  Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative study.

Authors:  Ming-De Lu; Hui-Xiong Xu; Xiao-Yan Xie; Xiao-Yu Yin; Jun-Wei Chen; Ming Kuang; Zuo-Feng Xu; Guang-Jian Liu; Yan-Lin Zheng
Journal:  J Gastroenterol       Date:  2005-11       Impact factor: 7.527

2.  Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?

Authors:  Tito Livraghi; Franca Meloni; Michele Di Stasi; Emanuela Rolle; Luigi Solbiati; Carmine Tinelli; Sandro Rossi
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

3.  Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma.

Authors:  Su Jung Shim; Jinsil Seong; Kwang Hyub Han; Chae Yoon Chon; Chang Ok Suh; Jong Tae Lee
Journal:  Liver Int       Date:  2005-12       Impact factor: 5.828

4.  A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.

Authors:  Shuichiro Shiina; Takuma Teratani; Shuntaro Obi; Shinpei Sato; Ryosuke Tateishi; Tomonori Fujishima; Takashi Ishikawa; Yukihiro Koike; Haruhiko Yoshida; Takao Kawabe; Masao Omata
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

5.  Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma.

Authors:  Mitsuhiko Kawashima; Junji Furuse; Teiji Nishio; Masaru Konishi; Hiroshi Ishii; Taira Kinoshita; Michitaka Nagase; Keiji Nihei; Takashi Ogino
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

6.  Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy.

Authors:  Toshiya Shibata; Yuji Iimuro; Yuzo Yamamoto; Yoji Maetani; Fumie Ametani; Kyo Itoh; Junji Konishi
Journal:  Radiology       Date:  2002-05       Impact factor: 11.105

7.  Treatment of portal vein tumor thrombosis of hepatoma patients with either stereotactic radiotherapy or three-dimensional conformal radiotherapy.

Authors:  Chun-Shu Lin; Yee-Min Jen; Su-Yun Chiu; Jing-Min Hwang; Hsing-Lung Chao; Hon-Yi Lin; Weng-Yoon Shum
Journal:  Jpn J Clin Oncol       Date:  2006-04-13       Impact factor: 3.019

8.  Comparison of therapeutic effects between radiofrequency ablation and percutaneous microwave coagulation therapy for small hepatocellular carcinomas.

Authors:  Kenji Ohmoto; Naoko Yoshioka; Yasuyuki Tomiyama; Norikuni Shibata; Tomoya Kawase; Koji Yoshida; Makoto Kuboki; Shinichiro Yamamoto
Journal:  J Gastroenterol Hepatol       Date:  2008-09-24       Impact factor: 4.029

9.  Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma.

Authors:  Wei-Jian Guo; Er-Xin Yu; Lu-Ming Liu; Jie Li; Zhen Chen; Jun-Hua Lin; Zhi-Qiang Meng; Yi Feng
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

Review 10.  Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Mao-Bin Meng; Yao-Li Cui; You Lu; Bin She; Yan Chen; Yong-Song Guan; Rui-Ming Zhang
Journal:  Radiother Oncol       Date:  2008-11-29       Impact factor: 6.280

View more
  16 in total

1.  Ultrasound-ultrasound image overlay fusion improves real-time control of radiofrequency ablation margin in the treatment of hepatocellular carcinoma.

Authors:  Yasunori Minami; Tomohiro Minami; Satoru Hagiwara; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Takamichi Murakami; Masatoshi Kudo
Journal:  Eur Radiol       Date:  2017-12-01       Impact factor: 5.315

Review 2.  Ultrasound fusion imaging technologies for guidance in ablation therapy for liver cancer.

Authors:  Yasunori Minami; Masatoshi Kudo
Journal:  J Med Ultrason (2001)       Date:  2020-02-08       Impact factor: 1.314

3.  Functional Liver Imaging in Radiotherapy for Liver Cancer: A Systematic Review and Meta-Analysis.

Authors:  Pi-Xiao Zhou; Ying Zhang; Quan-Bin Zhang; Guo-Qian Zhang; Hui Yu; Shu-Xu Zhang
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

4.  In vivo detection of distal tumor glycolytic flux stimulated by hepatic ablation in a breast cancer model using hyperpolarized 13C MRI.

Authors:  J Scott Goodwin; Leo L Tsai; David Mwin; Patricia Coutinho de Souza; Svayam Dialani; John T Moon; Zheng Zhang; Aaron K Grant; Muneeb Ahmed
Journal:  Magn Reson Imaging       Date:  2021-04-24       Impact factor: 3.130

5.  Long non-coding RNA CASC2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CASC2/miR-367/FBXW7 axis.

Authors:  Yufeng Wang; Zhikui Liu; Bowen Yao; Qing Li; Liang Wang; Cong Wang; Changwei Dou; Meng Xu; Qingguang Liu; Kangsheng Tu
Journal:  Mol Cancer       Date:  2017-07-17       Impact factor: 27.401

6.  Implication of Psoas Muscle Index on Survival for Hepatocellular Carcinoma Undergoing Radiofrequency Ablation Therapy.

Authors:  Yukihisa Yuri; Hiroki Nishikawa; Hirayuki Enomoto; Akio Ishii; Yoshinori Iwata; Yuho Miyamoto; Noriko Ishii; Kunihiro Hasegawa; Chikage Nakano; Takashi Nishimura; Kazunori Yoh; Nobuhiro Aizawa; Yoshiyuki Sakai; Naoto Ikeda; Tomoyuki Takashima; Ryo Takata; Hiroko Iijima; Shuhei Nishiguchi
Journal:  J Cancer       Date:  2017-06-01       Impact factor: 4.207

7.  1000 consecutive ablation sessions in the era of computer assisted image guidance - Lessons learned.

Authors:  Marie Beermann; Johan Lindeberg; Jennie Engstrand; Karolina Galmén; Silja Karlgren; David Stillström; Henrik Nilsson; Piotr Harbut; Jacob Freedman
Journal:  Eur J Radiol Open       Date:  2018-12-05

8.  131I-Labeled Copper Sulfide-Loaded Microspheres to Treat Hepatic Tumors via Hepatic Artery Embolization.

Authors:  Qiufang Liu; Yuyi Qian; Panli Li; Sihang Zhang; Jianjun Liu; Xiaoguang Sun; Michael Fulham; Dagan Feng; Gang Huang; Wei Lu; Shaoli Song
Journal:  Theranostics       Date:  2018-01-01       Impact factor: 11.556

9.  Effects of hepatic arterial infusion chemotherapy in the treatment of hepatocellular carcinoma: A meta-analysis.

Authors:  Guan-Bao Long; Chao-Wen Xiao; Xin-Yang Zhao; Jun Zhang; Xin Li
Journal:  Medicine (Baltimore)       Date:  2020-06-26       Impact factor: 1.817

10.  Long non-coding RNA CRNDE promotes the proliferation, migration and invasion of hepatocellular carcinoma cells through miR-217/MAPK1 axis.

Authors:  Haihao Wang; Ji Ke; Qiannan Guo; Kan-Paatib Barnabo Nampoukime; Peiwen Yang; Ke Ma
Journal:  J Cell Mol Med       Date:  2018-09-24       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.